Literature DB >> 27927882

The Japanese LupusPRO: A cross-cultural validation of an outcome measure for lupus.

M Inoue1, K Shiozawa2, R Yoshihara2, T Yamane3, Y Shima4, T Hirano4, M Jolly5, K Makimoto1.   

Abstract

Objective This study aimed to validate the Japanese version of the LupusPRO questionnaire for use with systemic lupus erythematosus patients. Methods Participants were 205 lupus patients recruited from three rheumatology centers in Japan. Demographic data were collected and quality of life was assessed using the LupusPRO and the Short Form Health Survey-12. Disease activity was evaluated by physicians using the Systemic Lupus Erythematosus Activity Index. Some participants completed questionnaires 10-14 days after the first survey. Internal consistency reliability, test-retest reliability, content validity and convergent validity were examined, and confirmatory factor analysis was performed. Results Participants' mean age was 47.8 ± 13.6 years. Older participants scored lower on physical quality of life and higher on coping than younger participants. The LupusPRO showed satisfactory test-retest reliability ( n = 111). Test-retest reliability was lower for the mental and social aspects of quality of life, indicating fluctuations in quality of life during the two-week interval. Internal consistency reliability was good and convergent validity with the corresponding domains of the Short Form Health Survey-12 was satisfactory. Confirmatory factor analysis showed a good model fit. Conclusion The Japanese LupusPRO is a reliable and valid measure to evaluate treatment interventions for systemic lupus erythematosus.

Entities:  

Keywords:  Systemic lupus erythematosus; patient-reported outcomes; quality of life

Mesh:

Year:  2016        PMID: 27927882     DOI: 10.1177/0961203316682100

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

1.  Predictors of poor sleep quality in patients with systemic lupus erythematosus.

Authors:  M Inoue; K Shiozawa; R Yoshihara; T Yamane; Y Shima; T Hirano; K Makimoto
Journal:  Clin Rheumatol       Date:  2017-01-30       Impact factor: 2.980

2.  Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study.

Authors:  Worawit Louthrenoo; Nuntana Kasitanon; Eric Morand; Rangi Kandane-Rathnayake
Journal:  Arthritis Res Ther       Date:  2020-01-10       Impact factor: 5.156

3.  Patient-reported outcome measures for use in clinical trials of SLE: a review.

Authors:  Zara Izadi; Julie Gandrup; Patricia P Katz; Jinoos Yazdany
Journal:  Lupus Sci Med       Date:  2018-08-21

4.  Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study.

Authors:  Yoshia Miyawaki; Sayaka Shimizu; Yusuke Ogawa; Ken-Ei Sada; Yu Katayama; Yosuke Asano; Keigo Hayashi; Yuriko Yamamura; Sumie Hiramatsu-Asano; Keiji Ohashi; Michiko Morishita; Haruki Watanabe; Mariko Takano-Narazaki; Yoshinori Matsumoto; Nobuyuki Yajima; Ryusuke Yoshimi; Yasuhiro Shimojima; Shigeru Ohno; Hiroshi Kajiyama; Kunihiro Ichinose; Shuzo Sato; Michio Fujiwara; Hajime Yamazaki; Yosuke Yamamoto; Jun Wada; Shunichi Fukuhara
Journal:  Arthritis Res Ther       Date:  2021-03-10       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.